Patents by Inventor Ann Marie Rowley

Ann Marie Rowley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tricyclic modulators of TNF signaling
    Patent number: 10266532
    Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: April 23, 2019
    Assignee: AbbVie Inc.
    Inventors: Eric C. Breinlinger, Phil B. Cox, Justin D. Dietrich, Kristine E. Frank, Michael M. Friedman, Huan-Qui Li, Kenton L. Longenecker, Augustine T. Osuma, Ann Marie Rowley, Anil Vasudevan, Noel S. Wilson, Jerome Daanen, Stevan Djuric, Amanda W. Dombrowski, Arthur Gomtsyan, Robert Schmidt
  • TRICYCLIC MODULATORS OF TNF SIGNALING
    Publication number: 20180179198
    Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
    Type: Application
    Filed: December 1, 2017
    Publication date: June 28, 2018
    Inventors: Eric C. Breinlinger, Phil B. Cox, Justin D. Dietrich, Kristine E. Frank, Michael M. Friedman, Huan-Qui Li, Kenton L. Longenecker, Augustine T. Osuma, Ann Marie Rowley, Anil Vasudevan, Noel S. Wilson
  • Tricyclic modulators of TNF signaling
    Patent number: 9856253
    Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: January 2, 2018
    Assignee: AbbVie, Inc.
    Inventors: Eric C. Breinlinger, Phil B. Cox, Justin Dietrich, Kristine E. Frank, Michael M. Friedman, Huan-Qui Li, Kenton Longenecker, Augustine Osuma, Ann Marie Rowley, Anil Vasudevan, Noel Wilson
  • TRICYCLIC MODULATORS OF TNF SIGNALING
    Publication number: 20160304517
    Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
    Type: Application
    Filed: April 15, 2016
    Publication date: October 20, 2016
    Inventors: Eric C. Breinlinger, Phil B. Cox, Jerome Daanen, Justin Dietrich, Stevan Djuric, Amanda W. Dombrowski, Kristine E. Frank, Michael M. Friedman, Arthur Gomtsyan, Huan-Qui Li, Kenton Longenecker, Augustine Osuma, Ann Marie Rowley, Robert Schmidt, Anil Vasudevan, Noel Wilson